NCT01405248View on ClinicalTrials.gov

Butylphthalide for Preventing Restenosis After Intracranial and Extracranial Artery Stenting

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Restenosis
Interventions
DRUG

Butylphthalide

20 mg/time per os three times a day. 180days

DRUG

Placebo

20 mg/time per os three times a day. 180days

Trial Locations (1)

210002

Department of Neurology ;Jinling Hospital, Nanjing

Sponsors
All Listed Sponsors
collaborator

CSPC-NBP Pharmaceutical Co., Ltd.

INDUSTRY

lead

Jinling Hospital, China

OTHER